Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Section 3 of 6

Product information and disease description

377 evidence topics · 152 sources

Product description

Phase of product development

Launch

No evidence found.

Development in other indications: cold urticaria, symptomatic dermographism, atopic dermatitis, prurigo nodularis, and eosinophilic esophagitis
FDA expedited program designations for chronic spontaneous urticaria

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Proprietary name

No evidence found.

Dosage forms and strengths
Strength and concentration per pre-filled syringe

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Humanized monoclonal antibody that binds KIT and blocks SCF binding and KIT dimerization
Allosteric inhibition through the membrane-proximal dimerization domains of KIT
Fc substitutions that abolish effector function and reduce clearance
Pharmacodynamics
Serum tryptase and plasma SCF in CSU: phase 1b, intravenous dosing every 4 or 8 weeks

“Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo): 0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Serum tryptase, a specific marker for MCs, was suppressed at all barzolvolimab doses, and reduction below assay detection levels was generally observed at doses ≥ 1.5 mg/kg (Figure 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Maximal tryptase suppression and clinical activity were reached at doses ≥ 1.5 mg/kg, which are consistent with target saturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Plasma SCF increases mirrored the tryptase suppression kinetics, and both correlated well with clinical activity (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The lowest dose (0.5 mg/kg) showed transient improvements in clinical activity that correlated with partial tryptase suppression, SCF increases, and subsequent recovery prior to the following dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All KIT‐dependent functions, including tissue MCs, hematological parameters, and hair color changes, are expected to recover once KIT signaling resumes following drug clearance, as has been observed in prior studies with barzolvolimab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Baseline serum tryptase in CSU compared with healthy participants, and response by baseline tryptase: phase 2 post hoc analysis
TimepointResponse definitionArea under the ROC curve for baseline serum tryptase
Week 12UAS7 = 0“0.49”
Week 12UAS7 ≤6“0.53”
Week 52UAS7 = 0“0.51”
Week 52UAS7 ≤6“0.56”
Serum tryptase and plasma SCF in healthy volunteers: single intravenous doses

“A single ascending dose (0.3, 1, 3, and 9 mg/kg), double‐blinded placebo‐controlled phase 1a human healthy volunteer study (n = 32) was conducted to evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX‐0159.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Tryptase reduction was manifest in all subjects dosed with CDX‐0159 at 24 h after the infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At the lowest dose of 0.3 mg/kg, plasma tryptase was reduced by approximately 50%, including the subject with high baseline tryptase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At higher doses, tryptase levels were reduced below the lower limit of assay quantitation (LLoQ) (1 ng/ml) in all CDX‐0159 treated subjects for at least 3 weeks at 1 mg/kg, 6–14 weeks at 3 mg/kg and over 18 weeks at 9 mg/kg (Figure 4B and Figure S10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No significant change in tryptase was observed in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We observed dose‐proportional increases in SCF levels that mirrored the effects of CDX‐0159 on plasma tryptase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Together with the effect of the antibody on tryptase levels, these data provide additional evidence of systemic KIT saturation with CDX‐0159 at doses of 1 mg/kg and above.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Chronic inducible urticaria: kinetics of skin mast cell depletion and repopulation to Week 36
Eosinophilic esophagitis: esophageal intraepithelial mast cell counts at Week 12, phase 2

“This randomized, double-blind, placebo-controlled, parallel group Phase 2 study is evaluating the efficacy and safety profile of subcutaneous barzolvolimab in patients with active EoE.” (opens the source at this quote in a new tab)

“65 patients were randomly assigned on a 1:1 ratio to receive subcutaneous injections of barzolvolimab at 300 mg every 4 weeks or placebo during a 16-week placebo-controlled treatment phase.” (opens the source at this quote in a new tab)

“Peak mast cell counts (CD117 positive cells) per high power field (hpf) at baseline were 50.3 in the placebo arm and 55.4 in the barzolvolimab 300mg Q4W arm.” (opens the source at this quote in a new tab)

“At Week 12 the absolute change from baseline was -2.7 for placebo compared to -36.0 for barzolvolimab [Diff (95%CI): -33.3 (-44.1, -22.6); p=<0.0001)].” (opens the source at this quote in a new tab)

“Mast cells defined by tryptase staining also showed profound decreases at week 12 in barzolvolimab treated patients with sustained and deepening decreases observed at Week 28.” (opens the source at this quote in a new tab)

“Despite profound mast cell depletion, no definitive evidence of clinical improvement in EoE symptoms, as measured by the Dysphagia Symptom Questionnaire (DSQ) (p=0.33), or endoscopic scoring of EoE-related inflammation & fibrosis (EREFS) (p=0.95) were observed compared to placebo.” (opens the source at this quote in a new tab)

“There was also no difference observed in histological reduction in esophageal intraepithelial infiltration of eosinophils (p=0.57).” (opens the source at this quote in a new tab)

Nonclinical toxicology in cynomolgus monkeys: bone marrow, red blood cell mass, and hair color

“To support human trials, a GLP‐compliant toxicology study was performed with CDX‐0159 in cynomolgus monkeys with dose levels of 1, 10, and 75 mg/kg administered every two weeks for 13 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“CDX‐0159 was well tolerated with no significant changes in body weight, coagulation, clinical chemistry, ophthalmology, electrocardiography, respiratory, or neurological function during the treatment and recovery period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Observations attributed to CDX‐0159‐included minimal increases in the myeloid to erythroid ratio in bone marrow smears in the animals dosed at 10 and 75 mg/kg at the end of dosing (day 85), with evidence of recovery by day 141 despite continued drug exposure in the recovery period (Figure 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In addition, recoverable minimal/mild decreases in red blood cell mass parameters were observed (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Hair color changes were noted in some high‐dose‐treated animals, consistent with inhibition of KIT activity in follicular melanocytes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Pharmacokinetics
Healthy volunteers, single intravenous doses: dose-proportional exposure and terminal half-life
Healthy volunteers, single subcutaneous doses of 50 to 600 mg
Subcutaneous bioavailability, time to peak concentration, and half-life

No evidence found.

CSU, multiple doses: dose-linear exposure, accumulation, and target saturation

“Given the sustained tryptase suppression and prolonged serum half‐life observed in the single‐dose study, two dose schedules were evaluated: once every 4 weeks (Q4W) and every 8 weeks (Q8W).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“PK parameters were calculated using noncompartmental methods and summarized using descriptive statistics to compare exposure in single and multiple dose settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Multiple doses of barzolvolimab resulted in prolonged exposure through 24 weeks in the ≥ 1.5‐mg/kg dose levels (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Maximum serum concentration (Cmax) and AUC increased in a linear fashion with increasing dose (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Increased clearance and lower volumes of distribution were observed in patients who received lower doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Barzolvolimab levels accumulated through multiple dosing cycles at all dose levels, and exposure by Cmax and AUC increased linearly with dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Target saturation was observed with a durable clinical response and tryptase suppression with doses ≥ 1.5 mg/kg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Immunogenicity in the phase 2 and phase 3 CSU trials

No evidence found.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information for Barzolvolimab

Not applicable.

Adverse events through the Week 24 placebo-controlled period: pooled EMBARQ-CSU1 and EMBARQ-CSU2
Adverse event, n (%)Placebo Q4WBarzolvolimab 150 mg Q4WBarzolvolimab 300 mg Q8W
Participants (N)“N=645”“N=648”“N=641”
Participants with at least 1 adverse event“340 (52.7)”“490 (75.6)”“492 (76.8)”
Hair color changes“29 (4.5)”“292 (45.1)”“330 (51.5)”
Skin hypopigmentation“16 (2.5)”“71 (11.0)”“64 (10.0)”
Neutropenia“4 (0.6)”“59 (9.1)”“75 (11.7)”
Skin hyperpigmentation“5 (0.8)”“59 (9.1)”“58 (9.1)”
Dysgeusia“9 (1.4)”“44 (6.8)”“63 (9.8)”
Hypogeusia“10 (1.6)”“33 (5.1)”“53 (8.3)”
Nasopharyngitis“36 (5.6)”“41 (6.3)”“40 (6.2)”
Anemia“4 (0.6)”“20 (3.1)”“20 (3.1)”
Participants with serious adverse events“15 (2.3)”“6 (0.9)”“14 (2.2)”
Treatment-related serious adverse events“1 (0.2)”“3 (0.5)”“4 (0.6)”
Hematologic laboratory decreases: phase 1b intravenous dosing in chronic spontaneous urticaria

“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Decreases in leukocytes, absolute neutrophil count, hemoglobin, and platelets were observed in patients after the first barzolvolimab dose when compared with placebo; no additional decreases were observed after subsequent doses (Figure S3). The majority of shifts were to Grades 1 and 2. A patient who received 4.5‐mg/kg barzolvolimab experienced a Grade 3 decrease in platelets; there was one patient also in the 4.5‐mg/kg group who experienced a Grade 2 decrease in WBC and did not receive the second dose per protocol; and three patients experienced Grade 3 decreased neutrophils (one in the 1.5‐mg/kg group and two in the 4.5‐mg/kg group); these all resolved during the study. There was no correlation of decreases with dose level. There were no trends of neutropenia correlating with increased infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most common AE related to treatment with barzolvolimab was mild hair color changes, followed by mild‐to‐moderate neutropenia, which was not associated with infections. Decreases in hematologic parameters were consistent with observations in healthy volunteers [10] and patients with chronic inducible urticaria [7] who received a single barzolvolimab dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Hair color and skin pigmentation changes: phase 2 through Week 76

“The objective of this analysis was to assess the rate and reversibility of pigmentation changes over 76 weeks in patients with CSU treated with barzolvolimab” (opens the source at this quote in a new tab)

“204 patients received ≥1 dose of barzolvolimab (any dose) and were included in this analysis” (opens the source at this quote in a new tab)

“Hair color changes (hypopigmentation) occurred in 49 (24%) patients; 96% of hair color changes were mild (Grade 1). Mean time to onset was ≈4 months, with 91% of evaluable patients reporting resolution of hair color change by the end of study participation” (opens the source at this quote in a new tab)

“Skin hypopigmentation occurred in 36 (18%) patients and events were mostly mild (94%; Grade 1); mean onset was ≈9 months, with 68% of evaluable patients reporting resolution by data cutoff” (opens the source at this quote in a new tab)

“Skin hyperpigmentation occurred in 6 (3%) patients, all of whom reported the events as mild (Grade 1); mean time to onset was ≈5 months, with 67% of evaluable patients reporting resolution by data cutoff” (opens the source at this quote in a new tab)

“Overall, 19 (9%) of patients reported concomitant hair color changes and skin hypopigmentation; 4 (2%) reported hair color changes and concomitant skin hyperpigmentation” (opens the source at this quote in a new tab)

“KIT-mediated hair color and skin pigmentation changes were observed in a subset of patients and were generally mild and reversible” (opens the source at this quote in a new tab)

CharacteristicHair color changesSkin hypopigmentationSkin hyperpigmentation
Participants with the event“n=49”“n=36”“n=6”
Grade 1, n (%)“47 (96)”“34 (94)”“6 (100)”
Time to onset from start of barzolvolimab, days, mean (range)“137 (7-397)”“271 (107-424)”“156 (11-283)”
Resolved at the time of data cutoff, n (%)“40 (91)”“19 (68)”“4 (67)”
Time to resolution on treatment, days, median (95% CI)“209 (119, 231)”“110 (60, 120)”“25 (7, NE)”
Time to resolution off treatment, days, median (95% CI)“168 (138,189)”“214 (196, 285)”“NE”
Discontinued study treatment due to event, n (%)“6 (3)”“0 (0)”“1 (<0.5)”
Phase 2 adverse events: placebo-controlled period to Week 16 and treatment period to Week 52
Participants, n (%)Barzolvolimab, all doses, Weeks 0 to 16Placebo, Weeks 0 to 16Barzolvolimab, all doses, Weeks 0 to 52Placebo then barzolvolimab, 36 weeks of barzolvolimab
Participants (N)“N= 156”“N= 51”“N= 156”“N=48”
At least one adverse event“103 (66)”“20 (39)”“139 (89)”“32 (67)”
Treatment-related serious adverse events“0”“0”“2 (1)”“0”
Hair color changes“22 (14)”“0”“40 (26)”“8 (17)”
Neutropenia or neutrophil count decreased“14 (9)”“0”“26 (17)”“2 (4)”
Urticaria“15 (10)”“5 (10)”“23 (15)”“3 (6)”
Skin hypopigmentation“2 (1)”“0”“21 (13)”“9 (19)”
Nasopharyngitis“6 (4)”“3 (6)”“15 (10)”“4 (8)”
Phase 1b adverse events at 24 weeks: intravenous dosing in chronic spontaneous urticaria
Chronic inducible urticaria phase 1b: single 3 mg/kg intravenous dose

“This is an ongoing single center, open-label Phase 1b study evaluating the safety/tolerability and clinical efficacy of a single dose of barzolvolimab in patients with CIndU refractory to SG-H1AHs.” (opens the source at this quote in a new tab)

“Single dose of barzolvolimab is administered intravenously on Day 1, and patients are followed for 12 weeks for safety, PD, and clinical activity assessments.” (opens the source at this quote in a new tab)

“Here, we report data from two cohorts of patients with ColdU and SD treated with a single dose of barzolvolimab (3 mg/kg) followed for 12 weeks as detailed below.” (opens the source at this quote in a new tab)

“Barzolvolimab was well tolerated (Table 2). All 21 patients reported AE. Most AEs were mild, and the most common (≥3 patients) were hair color changes (areas of hair lightening) (76%; n = 16/21), infusion reactions (43%; n = 9/21), taste changes (38%; n = 8/21), nasopharyngitis (24%; n = 5/21), malaise (24%; n = 5/21), and headache (19%; n = 4/21).” (opens the source at this quote in a new tab)

“Infusion reactions, which manifested as localized hives and itching as well as erythema and feeling hot, resolved spontaneously. One patient with a history of fainting experienced loss of consciousness during infusion; this event was not associated with MC activation based on decreasing tryptase values shortly after the event.” (opens the source at this quote in a new tab)

“Overall, mean hematology parameters remained within the normal ranges. Mild, transient, and asymptomatic decreases in hemoglobin and white blood cell parameters occurred for some patients (Figure S1).” (opens the source at this quote in a new tab)

Chronic inducible urticaria phase 2: Week 12 and Week 20 treatment periods

“We completed a Phase 2 study in patients with CIndU who remain symptomatic despite antihistamine therapy.” (opens the source at this quote in a new tab)

“Barzolvolimab was well tolerated with a favorable safety profile consistent with prior studies. Most adverse events were grade 1 (mild). Through 12 weeks, the most common treatment emergent adverse events in barzolvolimab treated patients were hair color changes (13%; Grade 1, n=15 / Grade 2, n=2) and neutropenia (10%; Grade 1, n=7 / Grade 2, n=6), which are mechanism related (KIT) and expected to be reversible. The rate of infections was similar between barzolvolimab-treated patients and placebo with no association between neutropenia and infections.” (opens the source at this quote in a new tab)

“Barzolvolimab was well tolerated with a favorable safety profile over the 20 week treatment period consistent with previous studies. There was no difference between active treatment (2%) and placebo groups (3%) in rate of discontinuations due to adverse events. Most adverse events for patients on study drug were grade 1 (mild), mechanism related (KIT) and, as demonstrated in previous studies, expected to be reversible. The most common adverse events occurring in greater than 10% of patients in any treatment group through Week 20 were hair color changes (18%; Grade 1, n=22 / Grade 2, n=2) and neutropenia (12%; Grade 1, n=9 / Grade 2, n=6). Neutropenia was transient and there was no association with infections.” (opens the source at this quote in a new tab)

Participants, n (%)Barzolvolimab 150 mg Q4WBarzolvolimab 300 mg Q8WAll barzolvolimabPlacebo
Participants (n)“n=65”“n=65”“n=130”“n=63”
Any adverse event“40 (62%)”“39 (60%)”“79 (61%)”“33 (52%)”
Treatment-related serious adverse events“0”“1 (2%)”“1 (1%)”“0”
Discontinued study treatment for adverse events“1 (2%)”“2 (3%)”“3 (2%)”“2 (3%)”
Hair color changes“9 (14%)”“8 (12%)”“17 (13%)”“0”
Neutropenia“4 (6%)”“9 (14%)”“13 (10%)”“0”
Healthy volunteers: single intravenous doses of 0.3 to 9 mg/kg

“placebo‐controlled phase 1a healthy volunteer study of CDX‐0159” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1). A CDX‐0159 intravenous infusion was well tolerated at all doses. The most common adverse event (AE)s observed in thirteen out of twenty‐four subjects who received CDX‐0159 were mild, self‐limited infusion reactions that were consistently described as areas of local itching associated with erythema, and induration/hives, which started during the infusions (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Mild decreases in hemoglobin levels generally within the normal range were observed, which rapidly stabilized despite the presence of high plasma drug levels (Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In addition, all CDX‐0159 treatment groups showed variable, asymptomatic decreases relative to placebo on circulating neutrophils, which were also reflected in the total leukocyte count and did not further decline during the course of the study (Figure 3B,C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In our healthy volunteer study, there were no reports of hair color changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Special populations
Pediatric participants

No evidence found.

Male fertility: spermatogenesis in the six-month non-human primate toxicology study
Renal impairment

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on Barzolvolimab
Clinical drug interaction studies

No evidence found.

Effects of Barzolvolimab on other drugs
Clinical drug interaction studies

No evidence found.

Dosing and administration
Dosage
Phase 3 regimens: 150 mg every 4 weeks after a 300 mg loading dose, or 300 mg every 8 weeks after a 450 mg loading dose
Dose regimen proposed for licensure

No evidence found.

Phase 2 regimens
Regimens with a 450 mg loading dose in cold urticaria, symptomatic dermographism, atopic dermatitis, and prurigo nodularis
Administration
Access and distribution
Commercial organization and commercial planning
Distribution channel and patient support model

No evidence found.

Co-prescribed/Concomitant therapies
Phase 1b add-on to H1 antihistamine alone or with H2 antihistamine or leukotriene receptor antagonist, with rescue antihistamines
Effect of Barzolvolimab on quality measures
AAAAI and ACAAI urticaria measures: laboratory test overuse and antihistamine updosing underuse
MeasureQuoted measure titleQuoted measure description
Urticaria Measure 1“Overuse: Laboratory Tests for Connective Tissue Disease”“Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent diagnostic testing for connective tissue disease in the absence of a history or symptoms consistent with or suggestive of a connective tissue disease.”
Urticaria Measure 2“Overuse: Laboratory Tests for Food Allergy”“Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent skin or in vitro testing for food allergies.”
Urticaria Measure 3“Overuse: Laboratory Tests for Inhalant Allergy”“Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent skin or in vitro testing for inhalant allergens.”
Urticaria Measure 4“Overuse: Laboratory Tests for Hereditary or Acquired Angioedema”“Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria with or without angioedema, who underwent diagnostic testing for a C1 inhibitor deficiency syndrome.”
Urticaria Measure 5“Underuse: Higher doses of Antihistamines”“The proportion of patients with chronic urticaria that is uncontrolled on monotherapy with approved doses of 2nd generation antihistamines, who are advanced as tolerated to one or more of the following: higher doses of second generation antihistamines; addition of another 2nd generation antihistamine, addition of a leukotriene antagonist, addition of an H2 blocker, or addition of a 1st generation antihistamine to be taken at bedtime.”
Product-specific effect on quality measures

No evidence found.

Product comparison

Place of product in therapy

Disease description

Definition and etiology
Classification by duration and by eliciting factors: acute versus chronic at 6 weeks, spontaneous versus inducible

“Urticaria is classified based on two main criteria: (i) its duration, as acute or chronic, and (ii) the role of definite triggers, categorized as inducible or spontaneous.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Acute urticaria is defined as the occurrence of wheals, angioedema or both for 6 weeks or less.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Chronic urticaria (CU) is defined as the occurrence of wheals, angioedema, or both for more than 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“When the clinical course has no definite physical eliciting factor involved and shows a spontaneous course, it is described as chronic spontaneous urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Inducible urticaria is characterized by the presence of definite and subtype‐specific triggers leading to the development of wheals, angioedema, or both” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that urticaria is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that urticaria is classified as spontaneous (no definite eliciting factor involved) or inducible (specific definite factor involved)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Chronic spontaneous urticaria as a share of chronic urticaria in the draft AAAAI/ACAAI JTF guideline
Epidemiology
Incidence of Chronic spontaneous urticaria
United States: incidence of diagnosed CSU in three US databases, 2012 to 2018, Novartis-funded

“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The data identification period for Optum EHR and Optum CDM was from January 1, 2012 to December 31, 2018, and for MarketScan it was January 1, 2012 to December 31, 2017.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The target population was identified using three anonymized databases: Optum Electronic Health Record (EHR), Optum Clinformatics Data Mart (CDM), and Truven Health MarketScan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Incident cohorts included newly identified patients with the first urticaria or angioedema code within the year of interest and no codes 12 months prior to that year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In Optum EHR, the age- and sex-standardized incidence rate (95% CI) among adults and pediatric patients during the identification period was 0.039 (0.039–0.039) and 0.066 (0.065–0.067) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The age-standardized incidence rate (95% CI) of CSU among the adult and pediatric populations during the identification period in Optum CDM was 0.094 (0.093–0.095) and 0.109 (0.107–0.111) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In MarketScan, the age-standardized incidence rate (95% CI) of CSU among adults and pediatric patients during the identification period was 0.102 (0.097–0.107) and 0.097 (0.096–0.098) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study also reports for the first time, to the best of our knowledge, standard incidence rate of diagnosed CSU in the USA, with period estimates among adults ranging from 0.039 to 0.102 per 100 person-years in the three databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

United States: combined adult and pediatric incidence of diagnosed CSU and annual trend, Novartis-funded study
Global: urticaria incidence in the Global Burden of Disease 2021 study
Prevalence of Chronic spontaneous urticaria
United States: diagnosed CSU period prevalence in three US databases, 2012 to 2018, Novartis-funded

“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study population consisted of adult (aged ≥ 18 years) and pediatric (aged < 18 years) patients with diagnosed CSU based on ≥ 2 relevant International Classification of Diseases version 9 and/or 10 (ICD-9 and/or ICD-10) codes recorded ≥ 6 weeks apart.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The age- and sex-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum EHR during the identification period (2012–2018) was 0.039 and 0.066 per 100 person-years, respectively, while the prevalence was 0.120% and 0.193%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum CDM (2012–2018) was 0.094 and 0.109 per 100 person-years, respectively, while the prevalence was 0.277% and 0.304%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in MarketScan (2012–2017) was 0.102 and 0.097 per 100 person-years, respectively, while the prevalence was 0.256% and 0.264%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Our study reports the standardized period prevalence of diagnosed CSU among adults from 0.120% to 0.277% across three databases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

United States: annual prevalence trend of diagnosed CSU, 2012 to 2018, Novartis-funded study
United States: 12-month prevalence of self-reported physician-diagnosed CSU of 0.78% in adults, 2019 National Health and Wellness Survey, Novartis-funded
Natural history, survival, and mortality
Remission rates at years 1, 5, and 20: targeted literature review
Pathophysiology
Mast cell activation as the central mechanism
Other cells, receptors, and pathways: T cells, B cells, eosinophils, basophils, MRGPRX2, complement, and coagulation
Biomarkers of type IIb autoimmune CSU: low total IgE, elevated IgG-anti-TPO, basopenia, eosinopenia, and basophil tests
KIT and stem cell factor: mast cell dependence on SCF/KIT signaling for survival and maturation
Mast cell depletion through KIT as a therapeutic mechanism
Diagnosis
Routine laboratory tests: differential blood count, CRP or ESR, total IgE, and IgG anti-TPO

“We recommend limited investigations. Basic tests include differential blood count, CRP and/or ESR, and in specialized care total IgE and IgG anti‐TPO, and more biomarkers as appropriate. We recommend performing further diagnostic measures based on the patient history and examination, especially in patients with long standing and/or uncontrolled disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The basic tests include a differential blood count, CRP and/or ESR (to rule out severe systemic disease, as an indicator for parasitic disease, eosinophilic count, autoimmune disease such as systemic lupus), in all patients. In patients under specialist care, additional tests, such as total IgE and IgG‐anti‐TPO may be performed, as they indicate the likelihood of response to omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“However, although a clinical association between these laboratory markers and urticaria endotypes has been demonstrated, their clinical usefulness remains limited because there are no studies evaluating their diagnostic accuracy. Currently, cutoff points can be suggested but cannot be recommended for definitive endotype classification” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Intensive and costly general screening programs for causes of urticaria are not advised.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Disease activity instruments: UAS7 and AAS recommendations and score ranges

“We recommend the use of the urticaria activity score, UAS7, and/or of the angioedema activity score, AAS, for assessing disease activity in patients with chronic spontaneous urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The UAS7, calculated as the sum of daily scores over 7 consecutive days, should be routinely used to monitor disease activity and treatment response in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For CSU patients who develop angioedema, with or without wheals, the Angioedema Activity Score (AAS) should be used to assess disease activity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“CSU patients who experience wheals and angioedema should use the UAS7 and the AAS in combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the UAS7 the sum of the score (0–3 for wheals +0–3 for pruritis) for each day is summarized over 1 week (7 days) for a maximum of 42.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the AAS, scores are summed up to an AAS day sum score (0–15), 7 AAS day sum scores to an AAS week sum score (AAS7, 0–105), and 4 ASS week sum scores may be summed up to an AAS 4‐week sum score (AAS28, 0–420).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Clinical presentation - signs and symptoms
Long-term morbidity
Corticosteroid-associated adverse events: United States claims cohort of 200,298 participants

“This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users. The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“When assessed according to corticosteroid user type, lipid disorders were the most common AE among patients in the ≤ 31D group (33.0%), and hypertension was the most frequent in the > 31 to ≤ 60D, > 60D, and ≥ 90Dc groups (38.0%, 44.0%, and 49.4%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The proportions of patients who reported skeletal conditions and avascular necrosis were ≥ 3 times higher in the ≥ 90Dc group versus non-users.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Burden of Chronic spontaneous urticaria
Humanistic burden and health-related quality of life
Quality of life, sleep, and work impairment in adults with CSU persisting 12 months or more despite treatment, Novartis-funded

“This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Almost 50% of patients had moderate‐to‐severe disease activity as reported by Urticaria Activity Score. Mean (SD) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1 (6.62) and 33.6 (20.99), respectively. Chronic spontaneous urticaria markedly interfered with sleep and daily activities. Angioedema in the previous 12 months was reported by 66% of enrolled patients and significantly affected HRQoL. More than 20% of patients reported ≥1 hour per week of missed work; productivity impairment was 27%. These effects increased with increasing disease activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The EQ‐5D‐3L domains for which patients most frequently reported moderate or extreme problems were pain/discomfort (63.2% of patients), anxiety/depression (47.4%), and usual activities (34.2%) (Figure 3C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Mean DLQI scores in this study suggest that CSU has a moderate impact on patients’ HRQoL,35 which is greater than previously thought; further, more than 40% had DLQI scores of 10 or greater, which, in psoriasis, justifies the initiation of a biologic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study was funded by Novartis Pharma AG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Adults with self-reported physician-diagnosed CSU, 2019 National Health and Wellness Survey: utilities, DLQI, anxiety, depression, and work impairment, Novartis-funded

“Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean (SD) SF-6D and EQ-5D health utility scores were 0.54 (0.14) and 0.62 (0.34), respectively. The mean (SD) DLQI score was 13.8 (11.2), with more than 74.0% of respondents reporting anxiety (GAD-7 ≥5) and depression (PHQ-9 ≥5). Mean percent (SD) scores for absenteeism, presenteeism, overall work impairment, and activity impairment were 36.5% (26.1), 67.2% (34.9), 73.1% (34.2), and 62.6% (34.1), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean (SD) DLQI score was 13.8 (11.2), with 54.2% of respondents having a score >10. More than one-third (36.5%) of respondents had a DLQI score between 21 and 30, indicating an extremely large effect on the patient's life (Fig. 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Chronic urticaria compared with psoriasis in France, Germany, Italy, Spain, and the United Kingdom, supported by Novartis and Genentech
Patient-reported burden by disease control in a multinational online survey, Novartis-funded
Economic burden and healthcare resource utilization
ASSURE-CSU: direct, indirect, and out-of-pocket costs by country and resource use

“Total average (SD) annual direct costs per patient per year, as captured in the retrospective medical record review, ranged from PPP$907.1 ($2431.14) in Italy to PPP$2984.2 ($8969.46) in France. The major drivers of these costs were therapies (range, PPP$426.4‐$1788.7) and inpatient visits (range, PPP$250.7‐$1074.4) (Tables S5 and S6 in Appendix S5 and S6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Average indirect costs, or costs of patient‐reported total work productivity loss over 4 weeks, were driven primarily by the cost of presenteeism (range, PPP$544.5‐$1180.0); the mean (SD) cost of work productivity loss ranged from PPP$544.8 ($603.22) in France to PPP$1287.4 ($1123.80) in Germany (Table S7 in Appendix S7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Moreover, in ASSURE‐CSU, CSU‐related out‐of‐pocket expenses to patients averaged nearly PPP$500 per year and approached PPP$1000 in Canada.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among the 97 patients (14.4%) with at least one CSU‐related ED visit in the past 12 months, the annual mean (SD) number of visits was 1.8 (1.26). Hospitalization for CSU was recorded for 55 patients (8.2%), with a mean (SD) length of stay per hospitalization of 3.7 (2.67) days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic impact of Chronic spontaneous urticaria on families
Family quality of life and household expenses by disease activity and control, international UCARE study

“This international cross‐sectional study was conducted in 12 countries across three continents, from January to December 2024 at Urticaria Centres of Reference and Excellence (UCARE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 1187 CSU patients and their respective family members completed questionnaires, including the Family Dermatology Life Quality Index (FDLQI), and physicians also provided clinical data on disease severity and control.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“FDLQI had a mean total score of 9.6 and mean scores varied across countries (Figure 1, Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“When stratified by UAS7 severity (minimal activity, mild, moderate, severe), family members of patients with higher disease activity reported significantly greater emotional distress, physical burden, social limitations and financial strain (Figure 3, Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Household expenses showed no statistically significant association with either severity (β = 0.27; CI95% –0.47 to 1.00) or control (β = −0.23; CI95% –0.53 to 0.06).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic impact of diagnostic testing

Not applicable.

Approaches to treatment

Current treatment options and standard of care
Second-generation h1 antihistamines
Dose-response network meta-analysis of 211 randomized trials for the Joint Task Force guideline update

“As part of updating the American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma & Immunology Joint Task Force on Practice Parameters Chronic Urticaria guidelines, we searched MEDLINE, EMBASE, CENTRAL, and regulatory databases from inception to March 17, 2025, for randomized trials addressing antihistamines or their adjuncts for chronic urticaria.” (opens the source at this quote in a new tab)

“Random effects network and dose–response meta-analyses addressed urticaria activity, angioedema activity, urticaria-related quality of life, and harms including sedation.” (opens the source at this quote in a new tab)

“A total of 211 trials (22,187 participants) evaluated 55 unique treatments. Bilastine, desloratadine, and fexofenadine are among the most effective in overall improvement. Cetirizine and loratadine are among the most effective in reducing overall urticaria activity and its subcomponents, with cetirizine also effective in improving urticaria-related quality of life.” (opens the source at this quote in a new tab)

“Dose–response meta-analyses suggest that there may be diminishing additional benefits beyond standard dosing (Fig 3, A; RD to improve by a minimal important difference with double dose: RD 8 more per 100 participants [95% CI, 7 to 9 more]; quadruple dose: RD 16 more [95% CI, 11 to 20 more]).” (opens the source at this quote in a new tab)

“Second-generation agents may result in a greater reduction compared to first-generation agents (MD −2.51 [95% CrI, −5.01 to −0.02]; RD 10 more [95% CrI, 0 to 19 more]; low certainty).” (opens the source at this quote in a new tab)

Response to updosing among standard-dose nonresponders: systematic review and meta-analysis

“The objective of this systematic review is to explore and analyse available data to provide clinical evidence for the efficacy of antihistamine updosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“We identified 1042 articles and 15 articles were included in the final evaluation. We performed two meta-analyses, one that included studies that analysed treatment response among groups receiving different antihistamine dosages vs. placebo, and another that analysed antihistamine updosing in those patients who did not respond to standard dosages.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Only five articles obtained a high quality level score. We did not find significant differences in response rates or number of weals in those patients who received a standard dosage vs. a high dosage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The estimated relative risk for improvement by increasing the antihistamine dosage was 2·27 [95% confidence interval (CI) 1·68-3·06]; however, there was significant heterogeneity. The proportion of nonrespondent patients with CSU who responded to antihistamine updosing was 63·2% (95% CI 57-69·6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Anti-IgE monoclonal antibodies
Omalizumab as add-on treatment after high-dose antihistamines: 2026 international guideline
Week 12 results with omalizumab 300 mg after antihistamines up to 4 times the approved dose plus H2-antihistamines or leukotriene receptor antagonists
Week 12 outcomeOmalizumab 300 mg (n = 252)Placebo (n = 83)
Change from baseline in UAS7, mean (95% CI)“−19.0 (−20.6 to −17.4)”“−8.5 (−11.1 to −5.9)”
UAS7 ≤6, no. (%)“132 (52.4)”“10 (12.0)”
UAS7 = 0, no. (%)“85 (33.7)”“4 (4.8)”
Drug survival and reasons for discontinuation: meta-analysis of 8 observational studies

“Observational clinical studies that reported on time to discontinuation or drug survival outcomes for omalizumab in patients with CU were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Eight studies comprising 4516 patients with CU (3167 female individuals [70.1%]; 3276 with chronic spontaneous urticaria [CSU]) were included. The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%). Early discontinuation was primarily due to well-controlled disease. Discontinuation due to adverse events was uncommon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The results of this systematic review and meta-analysis suggest that omalizumab demonstrates long-term drug survival in CU, with discontinuation more often due to disease control than adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Omalizumab in a network meta-analysis of systemic treatments for the Joint Task Force guideline update

“We systematically synthesized the comparative benefits and harms of systemic treatments for chronic urticaria.” (opens the source at this quote in a new tab)

“As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines” (opens the source at this quote in a new tab)

“Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events.” (opens the source at this quote in a new tab)

“We included 93 studies (n = 11,398; mostly adult and adolescent participants across 83 randomized trials and 10 nonrandomized studies) that evaluated 42 interventions. With high certainty, standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective for improving multiple patient-important outcomes.” (opens the source at this quote in a new tab)

“Standard-dose omalizumab (MD −8.37 [95% CrI −10.28 to −6.46]; high certainty), and remibrutinib (MD −7.65 [95% CrI −11.75 to −3.54]; high certainty) are among the most effective, while low-dose omalizumab (MD −5.25 [95% CrI −7.83 to −2.68]; high certainty) is among the intermediate effective.” (opens the source at this quote in a new tab)

“Standard-dose omalizumab (MD 8.75% more [95% CrI 1.93% to 15.56% more]; high certainty) and remibrutinib (MD 15.00% more [95% CrI 3.16% to 26.84% more]; high certainty) are among the most effective.” (opens the source at this quote in a new tab)

“Nonrandomized data (n = 149) suggest that 69% (95% CI 59% to 78%) of patients with disease refractory to standard-dose omalizumab may experience response (ie, UAS7 ≤ 6 or Urticaria Control Test [UCT] ≥ 12) with higher doses or more frequent administration.” (opens the source at this quote in a new tab)

“High-certainty evidence demonstrates that omalizumab (OR 0.92 [95% CrI 0.58 to 1.45]; RD 0.2% less [95% CrI 1% less to 1% more]) is not different from placebo” (opens the source at this quote in a new tab)

Anti-IL-4 receptor alpha monoclonal antibodies
CUPID Study A and Study C in anti-IgE-naive participants: Week 24 efficacy in the label
Week 24 outcomeStudy A dupilumab (N=68)Study A placebo (N=68)Study A difference or odds ratio (95% CI)Study C dupilumab (N=73)Study C placebo (N=75)Study C difference or odds ratio (95% CI)
ISS7, LS mean change (SE)“-10.44 (0.92)”“-6.02 (0.94)”“-4.42 (-6.84, -2.01)”“-8.50 (1.39)”“-6.13 (1.38)”“-2.37 (-4.48, -0.27)”
UAS7, LS mean change (SE)“-20.99 (1.77)”“-11.95 (1.81)”“-9.04 (-13.68, -4.40)”“-15.61 (2.62)”“-11.27 (2.61)”“-4.34 (-8.31, -0.36)”
UAS7 ≤6, n (%)“32 (47.1)”“16 (23.5)”“3.23 (1.43, 7.27)”“29 (39.7)”“17 (22.7)”“3.05 (1.32, 7.02)”
UAS7 = 0, n (%)“22 (32.4)”“9 (13.2)”“3.09 (1.24, 7.69)”“22 (30.1)”“13 (17.3)”“2.73 (1.15, 6.50)”
Bruton tyrosine kinase inhibitors
REMIX-1 and REMIX-2: design and Week 12 efficacy in the prescribing information
Outcome at Week 12REMIX-1 remibrutinib (N = 309)REMIX-1 placebo (N = 153)REMIX-2 remibrutinib (N = 297)REMIX-2 placebo (N = 153)
LS mean (SE) change in ISS7“-9.52 (0.34)”“-6.89 (0.47)”“-8.95 (0.34)”“-5.72 (0.45)”
LS mean (SE) change in HSS7“-10.47 (0.40)”“-6.86 (0.55)”“-10.47 (0.39)”“-6.00 (0.53)”
LS mean (SE) change in UAS7“-20.02 (0.72)”“-13.79 (0.98)”“-19.41 (0.70)”“-11.73 (0.95)”
UAS7 ≤6, n (%)“154 (49.8)”“38 (24.8)”“139 (46.8)”“30 (19.6)”
UAS7 = 0, n (%)“96 (31.1)”“16 (10.5)”“83 (27.9)”“10 (6.5)”
Treatment difference versus placebo at Week 12REMIX-1REMIX-2
UAS7 difference in LS mean (SE)“-6.22 (1.14)”“-7.68 (1.14)”
UAS7 95% CI for difference“-8.45, -4.00”“-9.91, -5.46”
UAS7 ≤6 treatment difference (95% CI)“25.44”“16.48, 34.39”“27.61”“19.14, 36.08”
UAS7 = 0 treatment difference (95% CI)“20.55”“13.35, 27.75”“21.60”“15.10, 28.10”
REMIX-1 and REMIX-2: Week 12 UAS7 outcomes and adverse events

“A total of 470 patients in REMIX-1 and 455 in REMIX-2 were randomly assigned to receive either remibrutinib (313 and 300 patients, respectively) or placebo (157 and 155 patients, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The remibrutinib group had a significantly greater decrease in the UAS7 at week 12 than the placebo group (least-squares mean [±SE] change, -20.0±0.7 vs. -13.8±1.0 [P<0.001] in REMIX-1 and -19.4±0.7 vs. -11.7±0.9 [P<0.001] in REMIX-2), which appeared to be sustained through week 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At week 12, significantly more patients in the remibrutinib group than in the placebo group had a UAS7 of 6 or lower (REMIX-1, 49.8% vs. 24.8% [P<0.001]; REMIX-2, 46.8% vs. 19.6% [P<0.001]) and a UAS7 of 0 (REMIX-1, 31.1% vs. 10.5% [P<0.001]; REMIX-2, 27.9% vs. 6.5% [P<0.001]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The percentages of patients with any adverse event and with serious adverse events were similar in the remibrutinib group and the placebo group, although a higher percentage of patients in the remibrutinib group than in the placebo group had petechiae (3.8% vs. 0.3% in the combined groups).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Funded by Novartis Pharmaceuticals;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Pooled REMIX-1 and REMIX-2: disease control, sleep, and quality of life through Week 52

“To evaluate the impact of remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor, on disease control, sleep, and QoL in CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) were phase 3, double-blind, placebo-controlled studies in adults with CSU who remained symptomatic despite receiving second-generation H1-antihistamines.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The pooled analysis included 606 and 306 patients receiving remibrutinib and placebo, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Within 1 week of starting remibrutinib, greater improvements in mean (SD) change from baseline (CFB) compared with placebo were noted in urticaria activity (CFB-Urticaria Activity Score: -11.8 [9.9] and -3.6 [7.6]) and sleep (CFB-Sleep Interference Score: -4.9 [4.9] and -1.9 [4.1]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Across assessments, responses were sustained through week 52 with remibrutinib, and comparable improvements were observed in those who transitioned to remibrutinib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Pooled REMIX-1 and REMIX-2 safety: bleeding, infections, cytopenia, and hepatic disorders
Rilzabrutinib: RILECSU phase 2 Week 12 results in antihistamine-refractory CSU

“What is the efficacy and risk profile of rilzabrutinib, an oral reversible covalent Bruton tyrosine kinase inhibitor, in adults with antihistamine-refractory chronic spontaneous urticaria (CSU)?” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The Rilzabrutinib Efficacy and Safety in CSU (RILECSU) randomized clinical trial was a 52-week phase 2 study comprising a 12-week, double-blind, placebo-controlled, dose-ranging period, followed by a 40-week open-label extension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients were randomized 1:1:1:1 to rilzabrutinib, 400 mg, once every evening (400 mg/d), twice per day (800 mg/d), 3 times per day (1200 mg/d), or matching placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary analysis population included only the 143 omalizumab-naive patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Significant reductions at week 12 were observed with rilzabrutinib, 1200 mg/d, vs placebo from baseline in ISS7 (least squares [LS] mean, −9.21 vs −5.77; difference, −3.44 [95% CI, −6.25 to −0.62]; P  = .02) and UAS7 (LS mean, −16.89 vs −10.14; difference, −6.75 [95% CI, −12.23 to −1.26]; P  = .02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Further research is needed to determine long-term efficacy and potential harms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Calcineurin inhibitors
Systemic corticosteroids for acute exacerbations
Corticosteroid use, adverse events, and health care resource use in a Novartis-funded US claims study

“This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“More frequent HCRU was generally observed after the first systemic corticosteroid prescription and with increasing duration of corticosteroid use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study and article publication, including the journal’s Rapid Service Fee, was funded by Novartis Pharmaceuticals Corporation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Limitations of current therapies
Summary: antihistamine-refractory and uncontrolled disease
  • Updosing: in a meta-analysis, 63·2% (95% CI 57 to 69·6) of participants with CSU who did not respond to a standard antihistamine dose responded to updosing; the authors state that study weakness and heterogeneity made a final conclusion difficult. A dose-response network meta-analysis of 211 trials (22,187 participants) suggested that there may be diminishing additional benefit beyond standard dosing (8 more per 100 participants improving by a minimal important difference with a double dose and 16 more with a quadruple dose).
  • Real-world control: in the AWARE study, sponsored by the manufacturer of omalizumab, uncontrolled CSU (UCT below 12) at Month 24 was reported in 23.2% (26 of 112) of participants on non-sedating H1-antihistamines, 41.9% (44 of 105) on updosed non-sedating H1-antihistamines, and 27.1% (78 of 288) on omalizumab.
  • US claims: proxy events for uncontrolled CSU (prescriptions for corticosteroids, biologics, or immunosuppressants, or CSU-related inpatient, emergency department, or urgent care visits) occurred in 59.1% of adults with diagnosed CSU, and, excluding over-the-counter medication and antihistamines, corticosteroids were the most prescribed treatment after diagnosis (78.3% of 200,298 adults; 68.2% systemic).
Summary: response and nonresponse to omalizumab
  • Week 12 response: in CSU Trial 1 of the label, UAS7=0 was reported in 36% with omalizumab 300 mg and 9% with placebo. In participants symptomatic despite H1-antihistamines at up to 4 times the approved dose plus H2-antihistamines or leukotriene receptor antagonists, UAS7 of 6 or less was reached by 132 (52.4%) with omalizumab 300 mg and 10 (12.0%) with placebo, and UAS7 = 0 by 85 (33.7%) and 4 (4.8%).
  • Insufficient response: the international guideline states that omalizumab at higher doses, shorter intervals, or both is off-label. Nonrandomized data (n = 149) suggest that 69% (95% CI 59% to 78%) of patients refractory to standard-dose omalizumab may respond with higher doses or more frequent administration. Type IIb autoimmune CSU is characterized by poor response to antihistamines and to omalizumab.
  • Persistence: in a meta-analysis of 8 observational studies (4516 participants), median omalizumab drug survival was 3.1 years, 7-year survival was 30% in CSU alone, and autoimmune comorbidity was associated with discontinuation for lack of efficacy (HR 2.03; 95% CI 1.20 to 3.41).
  • Safety: the label estimates anaphylaxis in at least 0.2% of patients from postmarketing reports and directs that omalizumab be initiated only in a healthcare setting equipped to manage anaphylaxis.
Summary: response and nonresponse to dupilumab and remibrutinib
  • Dupilumab: in anti-IgE-naive participants, UAS7 = 0 at Week 24 was reported in 22 (32.4%) with dupilumab and 9 (13.2%) with placebo in CUPID Study A, and in 22 (30.1%) and 13 (17.3%) in Study C. CUPID Study B, in 108 participants who were inadequate responders to or intolerant of anti-IgE treatment, did not meet its primary endpoint (ISS7 at Week 24). The international guideline states that dupilumab efficacy is likely to be less pronounced than that of omalizumab, and a network meta-analysis states that its impact on quality of life is uncertain and that no dupilumab trial addressed angioedema activity.
  • Remibrutinib: at Week 12, UAS7 = 0 was reported in 96 (31.1%) with remibrutinib and 16 (10.5%) with placebo in REMIX-1, and in 83 (27.9%) and 10 (6.5%) in REMIX-2. The label reports bleeding in 9% of patients treated with remibrutinib and 2% with placebo over the 24-week controlled period, requires interruption for 3 to 7 days before and after surgery, and advises avoiding use with strong or moderate CYP3A4 inhibitors or inducers and in hepatic impairment (Child-Pugh A, B, and C); safety and effectiveness have not been established in pediatric patients. The network meta-analysis commissioned for the US guideline states that the safety profile of remibrutinib is less certain.
Summary: ciclosporin and systemic corticosteroid harms, cost, and preferences
  • Ciclosporin is off-label for urticaria and the international guideline recommends it only for severe disease refractory to licensed treatments. In a meta-analysis of 18 studies (909 participants), response to low to moderate doses was 54%, 66%, and 73% at 4, 8, and 12 weeks, and 6%, 23%, and 57% of participants on very low, low, and moderate doses had 1 or more adverse events. The guideline states that ciclosporin is embryotoxic in animal models and associated with preterm delivery and low birth weight.
  • The international guideline recommends against long-term systemic corticosteroids and suggests a rescue course of up to 10 days for acute exacerbations. In US claims, the 10 most common adverse events after systemic corticosteroid initiation, including hypertension, lipid disorders, diabetes, and cataracts, occurred in higher proportions of corticosteroid users than non-users, and the proportion with adverse events generally increased with longer use.
  • The international guideline acknowledges that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost and that ciclosporin is restricted by its safety profile. Across 18 studies of patient values and preferences (28,497 participants), oral or topical treatments were favored over injections and infusions were least favored (moderate certainty).
Place in treatment, anticipated use, and care setting
Summary

The 2026 international guideline sequences treatment as a standard-dose second-generation H1-antihistamine first line, updosing up to 4-fold second line, then add-on omalizumab (recommended), dupilumab, or remibrutinib (both suggested) for CSU unresponsive to high-dose antihistamines, and off-label ciclosporin for CU unresponsive to licensed treatments. The guideline states that remibrutinib can be considered especially in patients who do not respond to both high-dose antihistamines and omalizumab, acknowledges cost restrictions on the three advanced therapies, and notes that treatments under development aim, among other approaches, to reduce mast cell numbers. A US Joint Task Force guideline that addresses the sequencing of conventional and advanced therapies was in draft for member review in 2026; the network meta-analysis commissioned for it rated standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib among the most effective with high certainty. In a primary care pathway, patients who remain symptomatic and adherent after up to four times the standard antihistamine dose should be referred for specialist evaluation, where total IgE and IgG-anti-TPO may be tested to indicate the likelihood of response to omalizumab. The barzolvolimab phase 3 trials, which study adults with CSU who remain symptomatic despite H1 antihistamine treatment, enrolled 1,939 participants, including advanced therapy-experienced or refractory participants, and are designed to detect a difference in an omalizumab-refractory subpopulation. The manufacturer describes barzolvolimab as positioned “as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.” It is supplied for the trials in 1 mL pre-filled syringes for subcutaneous injection, which the manufacturer states allows potential self-administration at home.

International guideline treatment algorithm: antihistamines, then omalizumab, dupilumab, or remibrutinib, then ciclosporin

“We recommend a 2nd generation H1-antihistamine as first-line treatment for all types of urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend updosing of a 2nd generation H1-antihistamine up to 4-fold in patients with chronic urticaria unresponsive to a standard-dosed 2nd generation H1-antihistamines as second-line treatment before other treatments are considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend adding on omalizumab* for the treatment of patients with CU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest using dupilumab* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest using remibrutinib* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest using ciclosporin* for the treatment of patients with CU unresponsive to licensed treatments or if these are not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Network meta-analysis commissioned for the draft US guideline: comparative effectiveness of systemic treatments
Heterogeneity of treatment effect
Barzolvolimab phase 3: complete response (UAS7=0) at Week 12, overall and in omalizumab-refractory participants
Population and arm, Week 12EMBARQ-CSU1EMBARQ-CSU2
Overall, placebo“9.3%”“12.6%”
Overall, 150 mg Q4W“42.4% (p<.00001)”“45.7% (p<.00001)”
Overall, 300 mg Q8W“42.1% (p<.00001)”“44.0% (p<.00001)”
Omalizumab-refractory, placebo“9.3%”“15.1%”
Omalizumab-refractory, 150 mg Q4W“55.3% (p<.00001)”“41.7% (p=.0089)”
Omalizumab-refractory, 300 mg Q8W“44.3% (p=.00017)”“46.4% (p=.0036)”
International guideline: biomarkers of response to omalizumab, dupilumab, ciclosporin, and antihistamines
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy